Scotiabank Remains a Buy on AbbVie (ABBV)
Scotiabank's Louise Chen maintained a Buy rating on AbbVie (ABBV) with a $280 price target. AbbVie reported Q2 revenue of $16.99B and net profit of $3.61B. Insider sentiment is negative, with recent sales by executives.
How this was made
The 30-second read
Why it matters
Earnings beat and analyst upgrades suggest short‑term upside, but insider selling adds caution.
Market read
AbbVie's earnings and upgraded targets could drive modest buying in the stock and sector.
What to watch
Potential headwinds from generic competition and pipeline risks.
Background
AbbVie reported Q2 revenue of $16.99B and net profit of $3.61B, up from prior year.
Ticker impact
Scotiabank and Piper Sandler reaffirm Buy ratings with a $280 price target after AbbVie's Q2 earnings release.
Potential modest price appreciation if market absorbs the higher target.
Buy rating and $280 target reflect confidence in earnings beat and growth outlook.
Market effects
Positive sentiment may lift other large‑cap pharma stocks.
U.S. healthcare sector may see modest gains.
Limited to U.S. and global pharma investors.
Counterpoint
Target may be overly optimistic given competitive pressures.
Key entities
- analystScotiabank
Maintained Buy rating with $280 target.
- analystPiper Sandler
Also issued a Buy rating.
- analystCiti
Maintained Hold rating.
